search
Back to results

Single-center Pathophysiological Study of the Role of Inflammation, Changes in the Intestinal Epithelial Barrier and the Intestinal Microbiota in Parkinson's Disease (IBIM-Park)

Primary Purpose

Parkinson's Disease

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Rectosignoidoscopy
Coloscopy
Sponsored by
Nantes University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Parkinson's Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Parkinson's Disease patients :

  • patients with Parkinson's disease according to the criteria of the United Kingdom Parkinson's disease survey brain bank (UKPDSBB)
  • aged over 18 years
  • who have given their consent to participate in this study

Idiopathic REM sleep behavior disorders patients:

  • patients with an Idiopathic REM sleep behavior disorder confirmed by video-polysomnography (International Classification of Sleep Disorders-3 criteria), not explained by a pathology (narcolepsy, brainstem injury, neurodegenerative disease)
  • aged over 18 years
  • having given their consent to participate in this study

Control:

  • patients undergoing coloscopy for family screening for digestive polyps
  • aged over 18
  • who have given their consent to participate in this study

Exclusion Criteria:

  • dementia (MINI MENTAL STATE EXAMINATION score <24)
  • history of authenticated colonic disease (inflammatory disease, adenocarcinoma) or functional colopathy in control subjects or having preceded the first signs of Parkinson's Disease or Idiopathic REM sleep behavior disorder for more than 5 years, respectively in Parkinson's Disease and Idiopathic REM sleep behavior disorder patients
  • history of prescription of antibiotic treatment, acute gastrointestinal illness or hospitalization for an acute medical pathology or for a surgical procedure in the last month
  • anticoagulant treatment or coagulopathy
  • pregnant or breastfeeding women, woman not benefiting from effective contraception if of childbearing age
  • adults under tutorship, curatorship or under legal protection

For patients with Idiopathic REM sleep behavior disorder:

- presence of Parkinson's Disease according to United Kindom Parkinson's Disease Brain Bank criteria

For control:

  • presence of a Parkinson's Disease according to United Kindom Parkinson's Disease Brain Bank criteria
  • complaint of nighttime unrest in favor of a probable Idiopathic REM sleep behavior disorder

Sites / Locations

  • Nantes Universitary HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Other

Other

Other

Other

Arm Label

Idiopathic REM sleep behavior disorders

Beginning Parkinson's disease

Parkinson's disease state Phase

Control

Arm Description

Group of 20 Patients with an Idiopathic REM sleep behavior disorder confirmed by video-polysomnography (International Classification of Sleep Disorders-3 criteria), not explained by a pathology (narcolepsy, brainstem injury, neurodegenerative disease)

Group of 20 patients with Parkinson's Disease which has been progressing for less than 5 years and who have not received dopatherapy

Group of 20 patients with Parkinson's Disease for more than 5 years

Group of 20 patients undergoing coloscopy for family screening for digestive polyps

Outcomes

Primary Outcome Measures

TNF-α
TNF-α in colonic biopsies measured by ELISA

Secondary Outcome Measures

IFN-γ
IFN-γ in colonic biopsies measured by ELISA
IL-6
IL-6 in colonic biopsies measured by ELISA
IL-1β
IL-1β in colonic biopsies measured by ELISA
IFN-α2
IFN-α2 in colonic biopsies measured by ELISA
MCP-1 (CCL2)
MCP-1 (CCL2) in colonic biopsies measured by ELISA
IL-8 (CXCL8)
IL-8 (CXCL8) in colonic biopsies measured by ELISA
IL-10
IL-10 in colonic biopsies measured by ELISA
IL-12p70
IL-12p70 in colonic biopsies measured by ELISA
IL-17A
IL-17A in colonic biopsies measured by ELISA
IL-18
IL-18 in colonic biopsies measured by ELISA
IL-23
IL-23 in colonic biopsies measured by ELISA
IL-33
IL-33 in colonic biopsies measured by ELISA
Permeability slopes for sulfonic acid
Permeability slopes for sulfonic acid (low molecular weight) and dextran (high molecular weight) measured in a Ussing chamber
Diversity of the intestinal microbiota
Bacterial diversity in each group by genetic sequencing of 16s RNA
Relative abundance of the intestinal microbiota
Relative abundance of different families or genera or bacterial species in each group by genetic sequencing of 16s RNA
Quantification of phosphorylated alpha-synuclein
Presence or absence of inclusion of phosphorylated alpha-synuclein, if presence: quantification (in thioflavin fluorescence intensity and amplification time in minutes)
Duration of progression
Disease duration of progression as Parkinson's disease clinical severity parameter
Age
Age as Parkinson's disease clinical severity parameter
Total Unified Parkinson Disease Rating Scale motor score
Total Unified Parkinson Disease Rating Scale motor score as Parkinson's disease clinical severity parameter
Unified Parkinson Disease Rating Scale axial sub-score
Unified Parkinson Disease Rating Scale axial sub-score as Parkinson's disease clinical severity parameter
Montreal Cognitive Assessment score
Montreal Cognitive Assessment score as Parkinson's disease clinical severity parameter
Presence or absence of a probable Idiopathic REM sleep behavior disorders
Presence or absence of a probable Idiopathic REM sleep behavior disorders (REM Sleep Behavior Disorder Screening Questionnaire score ≥ 5) as Parkinson's disease clinical severity parameter
Olfactory tests
Olfactory tests (Sniffin 'sticks test score) as Parkinson's disease clinical severity parameter
Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction score
Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction score as Parkinson's disease clinical severity parameter

Full Information

First Posted
November 25, 2020
Last Updated
December 20, 2021
Sponsor
Nantes University Hospital
Collaborators
France Parkinson Association, Luxia Scientific, INSERM - TENS - UMR 1235
search

1. Study Identification

Unique Protocol Identification Number
NCT04652843
Brief Title
Single-center Pathophysiological Study of the Role of Inflammation, Changes in the Intestinal Epithelial Barrier and the Intestinal Microbiota in Parkinson's Disease
Acronym
IBIM-Park
Official Title
Single-center Pathophysiological Study of the Role of Inflammation, Changes in the Intestinal Epithelial Barrier and the Intestinal Microbiota in Parkinson's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Recruiting
Study Start Date
December 17, 2020 (Actual)
Primary Completion Date
March 2023 (Anticipated)
Study Completion Date
June 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nantes University Hospital
Collaborators
France Parkinson Association, Luxia Scientific, INSERM - TENS - UMR 1235

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Converging evidence from the literature suggests that digestive inflammation may play a role in the development of Parkinson's disease (PD). The investigators showed in the laboratory in a pilot study that PD patients have digestive inflammation and that the level of inflammation was inversely related to the length of the disease course. This digestive inflammation could be at the origin of an increased intestinal permeability in a subpopulation of parkinsonian patients, cause or consequence of modifications of the intestinal microbiota, thus offering a potential portal of entry for a pathogen according to Braak's theory. To opponents of this theory, it could also reflect the spread of inflammation from the Central nervous System to the Enteral Nervous System (ENS), via the brain-gut axis. Investigators' hypothesis is that digestive inflammation occurs very early in Parkinson's disease and that it is associated with hyperpermeability of the intestinal epithelial barrier and a change in the intestinal microbiota composition. The investigators propose to study the inflammation markers in the ENS of patients with a pre-motor form of PD (idiopathic Rapid Eye Movement (REM) sleep behavior disorder, n = 20), early-stage PD (<5 years, without dopatherapy, n = 20), more advanced PD (> 5 years, n = 20) and control subjects (n = 20), on colonic biopsies taken during a rectosigmoidoscopy or a coloscopy. Intestinal permeability will be measured by ex-vivo techniques (in a Ussing chamber), the composition of the microbiota will be established by sequencing 16s RNA and the lesional load of phosphorylated alpha-synuclein will be evaluated by immunohistochemistry. All of these parameters will be correlated with clinical data on the severity of PD: duration of development, age, total Unified Parkinson's Disease Rating Scale (UPDRS) motor score and axial sub-score, cognitive tests (Montreal Cognitive Assessment, MoCA), existence of a probable idiopathic REM sleep behavior disorder (REM Sleep Behavior Disorder Screening Questionnaire RBDSQ), olfactory tests, complaint of dysautonomia (SCales for Outcomes in Parkinson's disease - autonomic dysfunction, SCOPA-Aut). The analysis of inflammation markers, the intestinal barrier and the microbiota could be a first step making it possible to formulate physiopathological hypotheses on the development of PD, to propose predictive biomarkers of the disease and its severity and to design early interventions in the hope of modifying the evolutionary course of the pathological process.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson's Disease

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Idiopathic REM sleep behavior disorders
Arm Type
Other
Arm Description
Group of 20 Patients with an Idiopathic REM sleep behavior disorder confirmed by video-polysomnography (International Classification of Sleep Disorders-3 criteria), not explained by a pathology (narcolepsy, brainstem injury, neurodegenerative disease)
Arm Title
Beginning Parkinson's disease
Arm Type
Other
Arm Description
Group of 20 patients with Parkinson's Disease which has been progressing for less than 5 years and who have not received dopatherapy
Arm Title
Parkinson's disease state Phase
Arm Type
Other
Arm Description
Group of 20 patients with Parkinson's Disease for more than 5 years
Arm Title
Control
Arm Type
Other
Arm Description
Group of 20 patients undergoing coloscopy for family screening for digestive polyps
Intervention Type
Procedure
Intervention Name(s)
Rectosignoidoscopy
Intervention Description
Rectosignoidoscopy for colonic biospsies collection
Intervention Type
Procedure
Intervention Name(s)
Coloscopy
Intervention Description
Coloscopy for colonic biospsies collection
Primary Outcome Measure Information:
Title
TNF-α
Description
TNF-α in colonic biopsies measured by ELISA
Time Frame
In the three months following the inclusion
Secondary Outcome Measure Information:
Title
IFN-γ
Description
IFN-γ in colonic biopsies measured by ELISA
Time Frame
In the three months following the inclusion
Title
IL-6
Description
IL-6 in colonic biopsies measured by ELISA
Time Frame
In the three months following the inclusion
Title
IL-1β
Description
IL-1β in colonic biopsies measured by ELISA
Time Frame
In the three months following the inclusion
Title
IFN-α2
Description
IFN-α2 in colonic biopsies measured by ELISA
Time Frame
In the three months following the inclusion
Title
MCP-1 (CCL2)
Description
MCP-1 (CCL2) in colonic biopsies measured by ELISA
Time Frame
In the three months following the inclusion
Title
IL-8 (CXCL8)
Description
IL-8 (CXCL8) in colonic biopsies measured by ELISA
Time Frame
In the three months following the inclusion
Title
IL-10
Description
IL-10 in colonic biopsies measured by ELISA
Time Frame
In the three months following the inclusion
Title
IL-12p70
Description
IL-12p70 in colonic biopsies measured by ELISA
Time Frame
In the three months following the inclusion
Title
IL-17A
Description
IL-17A in colonic biopsies measured by ELISA
Time Frame
In the three months following the inclusion
Title
IL-18
Description
IL-18 in colonic biopsies measured by ELISA
Time Frame
In the three months following the inclusion
Title
IL-23
Description
IL-23 in colonic biopsies measured by ELISA
Time Frame
In the three months following the inclusion
Title
IL-33
Description
IL-33 in colonic biopsies measured by ELISA
Time Frame
In the three months following the inclusion
Title
Permeability slopes for sulfonic acid
Description
Permeability slopes for sulfonic acid (low molecular weight) and dextran (high molecular weight) measured in a Ussing chamber
Time Frame
In the three months following the inclusion
Title
Diversity of the intestinal microbiota
Description
Bacterial diversity in each group by genetic sequencing of 16s RNA
Time Frame
In the three months following the inclusion
Title
Relative abundance of the intestinal microbiota
Description
Relative abundance of different families or genera or bacterial species in each group by genetic sequencing of 16s RNA
Time Frame
In the three months following the inclusion
Title
Quantification of phosphorylated alpha-synuclein
Description
Presence or absence of inclusion of phosphorylated alpha-synuclein, if presence: quantification (in thioflavin fluorescence intensity and amplification time in minutes)
Time Frame
In the three months following the inclusion
Title
Duration of progression
Description
Disease duration of progression as Parkinson's disease clinical severity parameter
Time Frame
At inclusion
Title
Age
Description
Age as Parkinson's disease clinical severity parameter
Time Frame
At inclusion
Title
Total Unified Parkinson Disease Rating Scale motor score
Description
Total Unified Parkinson Disease Rating Scale motor score as Parkinson's disease clinical severity parameter
Time Frame
At inclusion
Title
Unified Parkinson Disease Rating Scale axial sub-score
Description
Unified Parkinson Disease Rating Scale axial sub-score as Parkinson's disease clinical severity parameter
Time Frame
At inclusion
Title
Montreal Cognitive Assessment score
Description
Montreal Cognitive Assessment score as Parkinson's disease clinical severity parameter
Time Frame
At inclusion
Title
Presence or absence of a probable Idiopathic REM sleep behavior disorders
Description
Presence or absence of a probable Idiopathic REM sleep behavior disorders (REM Sleep Behavior Disorder Screening Questionnaire score ≥ 5) as Parkinson's disease clinical severity parameter
Time Frame
At inclusion
Title
Olfactory tests
Description
Olfactory tests (Sniffin 'sticks test score) as Parkinson's disease clinical severity parameter
Time Frame
At inclusion
Title
Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction score
Description
Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction score as Parkinson's disease clinical severity parameter
Time Frame
At inclusion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Parkinson's Disease patients : patients with Parkinson's disease according to the criteria of the United Kingdom Parkinson's disease survey brain bank (UKPDSBB) aged over 18 years who have given their consent to participate in this study Idiopathic REM sleep behavior disorders patients: patients with an Idiopathic REM sleep behavior disorder confirmed by video-polysomnography (International Classification of Sleep Disorders-3 criteria), not explained by a pathology (narcolepsy, brainstem injury, neurodegenerative disease) aged over 18 years having given their consent to participate in this study Control: patients undergoing coloscopy for family screening for digestive polyps aged over 18 who have given their consent to participate in this study Exclusion Criteria: dementia (MINI MENTAL STATE EXAMINATION score <24) history of authenticated colonic disease (inflammatory disease, adenocarcinoma) or functional colopathy in control subjects or having preceded the first signs of Parkinson's Disease or Idiopathic REM sleep behavior disorder for more than 5 years, respectively in Parkinson's Disease and Idiopathic REM sleep behavior disorder patients history of prescription of antibiotic treatment, acute gastrointestinal illness or hospitalization for an acute medical pathology or for a surgical procedure in the last month anticoagulant treatment or coagulopathy pregnant or breastfeeding women, woman not benefiting from effective contraception if of childbearing age adults under tutorship, curatorship or under legal protection For patients with Idiopathic REM sleep behavior disorder: - presence of Parkinson's Disease according to United Kindom Parkinson's Disease Brain Bank criteria For control: presence of a Parkinson's Disease according to United Kindom Parkinson's Disease Brain Bank criteria complaint of nighttime unrest in favor of a probable Idiopathic REM sleep behavior disorder
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Laurène LECLAIR-VISONNEAU, MD
Phone
+33 2 40 16 54 95
Email
Laurene.LECLAIR@chu-nantes.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Laurène LECLAIR-VISONNEAU, MD
Organizational Affiliation
Nantes University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nantes Universitary Hospital
City
Nantes
State/Province
Loire Atlantique
ZIP/Postal Code
44093
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laurene LECLAIR-VISONNEAU, MD
Phone
+33 2 40 16 54 95
Email
laurene.leclair@chu-nantes.fr
First Name & Middle Initial & Last Name & Degree
Laurene LECLAIR-VISONNEAU, MD
First Name & Middle Initial & Last Name & Degree
Emmanuel CORON, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Single-center Pathophysiological Study of the Role of Inflammation, Changes in the Intestinal Epithelial Barrier and the Intestinal Microbiota in Parkinson's Disease

We'll reach out to this number within 24 hrs